M&A Advisory
K&L Gates
Full Credential Description
Sentiss Pharma faced a significant challenge in expanding its capabilities and market presence within the pharmaceutical industry. The company sought to acquire Akorn AG Switzerland, which included a US FDA-approved sterile manufacturing plant and a diverse of approved products for the US market. This acquisition was crucial for Sentiss Pharma as it aimed to restore the supply of essential products, particularly for patients with significant respiratory issues, including children. K&L Gates LLP provided tailored legal assistance throughout the complex bankruptcy auction process, enabling Sentiss Pharma to successfully acquire Akorn AG. The legal team, led by partners Jonathan Barron and Lee Hogewood, along with associate Arielle Wisotsky, played a pivotal role in navigating the intricacies of the acquisition. The outcome of this strategic move not only allowed Sentiss Pharma to enhance its product offerings with high-demand items and abbreviated new drug applications (ANDAs) but also positioned the company to better serve the needs of US patients. As a result of this acquisition, Sentiss Pharma significantly expanded its capabilities and strengthened its global market presence, ultimately benefiting many patients who rely on their products.